Two experts in the management of extensive-stage small cell lung cancer provide an overview of chemotherapy-induced myelosuppression and share key insights into the myeloprotective benefit of the CDK4/6 inhibitor trilaciclib.
Dr Daniel Pollyea comments on the potential use of tamibarotene in patients that are newly diagnosed with acute myeloid leukemia (AML).
Dr Gustavo Rivero discusses how and where tamibarotene might fit into the treatment landscape for patients with higher-risk myelodysplastic syndrome (MDS).
Jennifer Atlas, MD, and Shahab Babakoohi, MD, discuss advances in the treatment of patients with basal cell carcinoma and their treatment approaches to clinical scenarios based on updated data.
An expert oncologist and pathologist discuss molecular testing in metastatic colorectal cancer and the current and upcoming options for HER2-targeted therapies.
Expert perspectives on recent evolutions with CDK4/6 inhibitors in the HR+, HER2- metastatic breast cancer treatment landscape.
Expert provides an overview of esophageal squamous cell carcinoma (ESCC), discusses several key updates to the treatment landscape, and elucidates how clinicians can improve patient outcomes by applying data from the treatment algorithm.
Richard Stone, MD, and Eunice Wang, MD, discuss recent advances in the treatment of newly-diagnosed acute myeloid leukemia and its impact on clinical practice.
Centering discussion on real-world patient scenarios, expert hematologist-oncologists review recent treatment advances in multiple myeloma with a focus on bispecifics and their impact on clinical practice.
Experts share insight on the evolving treatment armamentarium for myeloproliferative neoplasms.
Dr. Michael Atkins and Dr. Evan Lipson discuss the state of metastatic melanoma, contemporary and emerging treatment strategies, and break down a specific patient profile. Their conversation touches on the pros and cons of different treatment strategies for newly diagnosed patients as well as second- and third-line treatment strategies. Dr. Atkins and Dr. Lipson also take time to provide their personal experiences, preferences, and thoughts on prospects involving the treatment and management of metastatic melanoma.
Experts in the field of differentiated thyroid cancer highlight recent advances in treatment by reviewing two real-world patient scenarios.
Expert oncologists share updates on the testing and treatment of molecular alterations in advanced non-small cell lung cancer.
Shared insight on the evolving treatment armamentarium for metastatic CRPC and how expert physicians are optimizing care.
A discussion on recent advances in the treatment of advanced renal cell carcinoma and their impact on clinical practice, illustrated by real-world patient profiles.
Expert perspectives on historical and novel treatment strategies for patients diagnosed with chronic graft-versus-host disease.
Centering discussion on patient profiles, expert panelists review recent advances in the treatment of renal cell carcinoma and their impact on clinical practice.
This OncLive Insights features a medical oncologist and gynecologic oncologist who share their thoughts on the selection of first-line and subsequent therapy in advanced endometrial cancer. They discuss treatment strategies and novel therapeutics that may improve health outcomes in patients with the disease.
Expert gynecologic oncologists provide a discussion on the care of patients with endometrial carcinoma.
Insight regarding the utilization of antibody-drug conjugate therapy to treat relapsed/refractory advanced bladder cancer.
Nicole Lamanna, MD, and Nirav N. Shah, MD, discuss the use of BTK inhibitors as targeted therapy for chronic lymphocytic leukemia and recent advancements.
This OncLive Insights features three immune thrombocytopenia experts who share their approach to treating different patient populations, considerations when selecting treatments, and emerging therapies for this condition.
Recommendations for assessing and treating patients with relapsed/refractory B-cell ALL based on more recent data presented at ASH 2021.
Expert oncologists navigate the evolving treatment landscape of advanced or metastatic urothelial carcinoma.
An overview of the role of currently-available and emerging BCMA-targeting therapies in the treatment landscape for multiple myeloma.
David Gerber, MD, and Steven Vernino, PhD, provide a discussion on Lambert-Eaton Myasthenic Syndrome (LEMS), its association with small cell lung cancer, and the available treatment options.
Experts come together to share their perspective on the paradigm of previously treated Ph+ chronic myeloid leukemia.
Approaches to planning treatment for patients with newly diagnosed chronic lymphocytic leukemia, as recommended by healthcare professionals from Memorial Sloan Kettering Cancer Center.
Discussion of recent clinical trial updates in HER2-positive metastatic breast cancer and implications for managing 2 patient case scenarios.